CLINICAL TRIAL PATIENT TECHNOLOGY INSIGHTS
-
When The System Breaks, Who Pays? SCRS On Site Tech Gaps
SCRS CSSO Jimmy Bechtel on why clinical site tech integration is an architecture problem – and who bears the risk when remote systems fail.
-
HTA, Digital Twins, And Building Clinical Tech That Lasts
ISPOR CEO Rob Abbott on HTA-integrated trial design, digital twin evidence gaps, SaMD’s continuous update problem, and the one change he’d mandate for clinical tech.
ECOA RESOURCES
-
Hear from patients and caregivers across various therapeutic areas as they offer tips on improving the clinical trial experience.
-
The value of eCOA tools is undisputed, but using a waterfall methodology of software delivery is highly inefficient. Explore how a more agile approach to eCOA development can produce a fully functional eCOA in a day.
-
Discover how eCOA data capture can improve clinical trials by providing improved data quality, regulatory compliance, and accelerated clinical development.
ECONSENT RESOURCES
-
The shift towards decentralized and hybrid trials underscores the significance of EDC in expanding geographic reach, fostering diversity in participant populations, and reduce participant burden.
-
Despite the challenges associated with large volumes of data, maintaining quality and regulatory compliance, and enhancing patient engagement, the solutions for managing them can be simple and efficient.
-
A truly integrated eSource Solution, including DDC, eCOA, and eConsent, facilitates remote or decentralized clinical trials by ingesting data from multiple sources and consolidating it into a single data set.
EPRO RESOURCES
-
The shift towards decentralized and hybrid trials underscores the significance of EDC in expanding geographic reach, fostering diversity in participant populations, and reduce participant burden.
-
Discover how eCOA data capture can improve clinical trials by providing improved data quality, regulatory compliance, and accelerated clinical development.
-
Discover how an instruction program directly contributed to significantly lowering the placebo response rate in a phase III migraine CNS study.